Long-Term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 3, 2009, Pages 215-226

  Sallee, Floyd R ^a   Lyne, Andrew ^b   Wigal, Timothy ^c   McGough, James J ^d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Shire Pharmaceuticals   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; GUANFACINE; METHYLPHENIDATE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CHILD; CLINICAL TRIAL; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; EXTENDED RELEASE FORMULATION; FATIGUE; FEMALE; HEAD INJURY; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPOTENSION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHARYNGITIS; PULSE RATE; SEDATION; SIDE EFFECT; SINUS BRADYCARDIA; SOMNOLENCE; SUICIDAL IDEATION; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNCONSCIOUSNESS; WEIGHT GAIN;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GUANFACINE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 67650904184     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.0080     Document Type: Article

References (28)

1. Adler LA, Reingold LS, Morrill MS, Wilens TE: Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep8:409-415, 2006.
2. American Academy of Child and Adolescent Psychiatry: Practice parameter for the assessment and treatment of childrenand adolescents with attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry 47:894-921, 2007.
3. Arnsten AF, Cai JX, Goldman-Rakic PS: The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeyswithout sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes. J Neurosci 8:4287-4298, 1988.
4. Arnsten AF, Steere JC, Hunt RD: The contribution of a2- noradrenergic mechanisms to prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivitydisorder. Arch Gen Psychiatry 53:448-455, 1996.
5. Biederman J, Faraone SV: Attention-deficit hyperactivity disorder.Lancet 366:237-248, 2005.
6. Biederman J, Melmed RD, Patel A, McBurnett R, Konow J, Lyne A, Scherer N, for the SPD503 Study Group: A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121:e73-e84, 2008.
7. Brown RT, Freeman WS, Perrin JM, Stein MT, Amler RW, Feldman HM, Pierce K, Wolraich ML: Prevalence and assessment of attention-deficit/hyperactivity disorder in primarycare settings. Pediatrics 107:E43, 2001.
8. Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Arnsten A, Leckman JF, Cohen DJ: Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Touretté syndrome: Preliminary clinical experience. J Am Acad ChildAdolesc Psychiatry 34:1140-1146, 1995.
9. Connor DF, Barkley RA, Davis HT: A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. ClinPediatr (Phila) 39:15-25, 2000.
10. Connor DF, Fletcher KE, Swanson JM: A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder.J Am Acad Child Adolesc Psychiatry 38:1551-1559, 1999.
11. Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE, Jr, Palumbo D, Harris P, Sallee FR: Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry47:189-198, 2008.
12. Fenichel RR: Combining methylphenidate and clonidine: The role of post-marketing surveillance. J Child Adolesc Psychopharmacol5:155-156, 1995.
13. Hazell PL, Stuart JE: A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry42:886-894, 2003.
14. Hunt RD, Arnsten AFT, Asbell MD: An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder.J Am Acad Child Adolesc Psychiatry 34:50-54, 1995.
15. McIntyre RS, Fallu A, Konarski JZ: Measurable outcomes in psychiatric disorders: Remission as a marker of wellness. ClinTher 28:1882-1891, 2006.
16. Newcorn JH, Schulz K, Harrison M, DeBellis MD, Udarbe JK, Halperin JM: Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. PediatrClin North Am 45:1099-1022, viii, 1998.
17. Olfson M: New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care10(Suppl):S117-S124, 2004.
18. Palumbo DR, Sallee FR, Pelham WE, Jr, Bukstein OG, Daviss WB, McDermott MP: Clonidine for attention-deficit/ hyperactivity disorder: I. Efficacy and tolerability outcomes.J Am Acad Child Adolesc Psychiatry 47:180-188, 2008.
19. Pliszka SR, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M, and The Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder: The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry45:642-657, 2006.
20. Popper CW: Combining methylphenidate and clonidine: Pharmacologic questions and news reports about sudden death.J Child Adolesc Psychopharmacol 5:157-166, 1995.
21. Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents aged 6-17. http://www.clinicaltrials.gov/ct2/show/NCT00150618/. Accessed June 2, 2008.
22. Sallee F, McGough J, Wigal T, Donahue J, Lyne A, Biederman J, for the SPD503 Study Group: Guanfacine extended release in children and adolescents with attention deficit hyperactivity disorder: A placebo-controlled trial. J Am Acad Child AdolescPsychiatry 48:155-165, 2009.
23. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leckman JF: A placebocontrolled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.Am J Psychiatry 158:1067-1074, 2001.
24. Spencer T, Greenbaum M, Ginsberg LD, Murphy WR, Farrand K: Open-label coadministration of guanfacine extended release and stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Poster presented at: American Psychiatric Association's 161st Annual Meeting, May 3-8, 2008, Washington, DC.
25. Steele M, Jensen PS, Quinn DM: Remission versus response as the goal of therapy in ADHD: A new standard for the field?Clin Ther 28:1892-1908, 2006.
26. Swanson JM, Flockhart D, Udrea D, Cantwell DP, Connor D, Williams L: Clonidine in the treatment of ADHD: Questions about safety and efficacy. J Child Adolesc Psychopharmacol5:301-304, 1995.
27. Uhlé S, Wikberg JES: Delineation of rat kidney a2A- and a2Badrenoceptors with [3H]RX821002 radioligand binding: Computer modelling reveals that guanfacine is an a2A-selectivecompound. Eur J Pharmacol 202:235-243, 1991.
28. Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A, Vijayraghavan S, Brennan A, Dudley A, Nou E, Mazer JA, McCormick DA, Arnsten AF: a2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channelsignaling in prefrontal cortex. Cell 129:397-410, 2007.